MedTrace Logo

To Evaluate Efficacy of Monotherapy of Oxcarbazepine Versus Combination of Gabapentin With Oxcarbazepine in the Management of Trigeminal Neuralgia

NCT07625410 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-06-04

No results posted yet for this study

Summary

ABSTRACT:

Objective: This study evaluates the effectiveness of oxcarbazepine monotherapy with the combination of gabapentin and oxcarbazepine in managing trigeminal neuralgia(TN).

Methods: A prospective observational study was conducted at Rehman College of Dentistry for the duration of one year, i.e., from 1st May 2023 till May 2024. A total of 44 patients, fulfilling inclusion criteria, were included.Half were given monotherapy with oxcarbazepine (300 mg twice daily) and half were given combination therapy with gabapentin (100 mg daily) plus oxcarbazepine. Pain was evaluated utilizing the Visual Analogue Scale (VAS) at baseline, 2 weeks, and 2 months. SPSS software version 26 was used for statistical analysis.

KEYWORDS: Combination Therapy, Gabapentin, Monotherapy, Oxcarbazepine, Trigeminal Neuralgia, Visual Analogue Scale.

Conditions

  • Effectiveness of Drugs Was Compared for Treating Trigeminal Neuralgia
  • Pain
  • Pain Management

Interventions

DRUG

oxcarbamezapine(300 mg twice daily)

monotherapy with oxcarbamezapine(300 mg twice daily)

DRUG

combination therapy(oxcarbamezapine 300 mg twice daily and gabapentine)

combination therapy of oxcarbamezapine with gabapentine was given

Sponsors & Collaborators

  • Rehman Medical Institute - RMI

    lead OTHER

Principal Investigators

  • iftikhar qayum, MBBS, MD, PHD · Rehman Medical Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2024-05-01
Completion
2024-05-01

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07625410 on ClinicalTrials.gov